US equities |
NVDA $240.00 ▲+2.59% SPCX $169.61 ▲+6.70% MU $1,063.53 ▼-1.06% TSLA $379.75 ▲+2.47% SNDK $1,706.43 ▼-0.79% MSFT $528.89 ▲+2.20% INTC $116.16 ▼-2.65% META $743.13 ▲+2.07%
FinancialContent

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

31.49 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical ↗
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing. 
Via Benzinga
Topics Intellectual Property
News headline image
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva ↗
One of Catalyst's key products has protection against a knockoff from Teva until 2035. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NASDAQ:CPRX, a growth stock which is not overvalued. ↗
NASDAQ:CPRX is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. ↗
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Should you consider NASDAQ:CPRX for growth investing? ↗
Exploring growth characteristics of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. ↗
Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Arcellx Stock Earns 82 Relative Strength Rating ↗
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
News headline image
Neurocrine Biosciences Stock Sees RS Rating Upgrade ↗
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
Via Investor's Business Daily
News headline image
For those who appreciate value investing, NASDAQ:CPRX is a compelling option with its solid fundamentals. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Unlocking the Growth Potential of NASDAQ:CPRX. ↗
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s growth characteristics. 
Via Chartmill
News headline image
Why NASDAQ:CPRX qualifies as a high growth stock. ↗
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing? 
Via Chartmill
News headline image
Is NASDAQ:CPRX on the Verge of a Major Breakout as a Strong Growth Stock? ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95. 
Via Investor's Business Daily
News headline image
Don't overlook NASDAQ:CPRX—a stock with solid growth prospects and a reasonable valuation. ↗
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Despite its impressive fundamentals, NASDAQ:CPRX remains undervalued. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NASDAQ:CPRX is showing good growth, while it is not too expensive. ↗
NASDAQ:CPRX is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
NASDAQ:CPRX is an undervalued gem with solid fundamentals. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). ↗
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
BioNTech Stock Got A IBD RS Rating Lift ↗
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Vericel Stock Sees RS Rating Shoot Higher ↗
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
News headline image
A Peek at Catalyst Pharmaceuticals's Future Earnings ↗
 
Via Benzinga
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >